Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Dose Reduction in RA (ADDORA-low)
NCT04222920Phase 4Completed
- Sponsor
- Reade Rheumatology Research Institute
- Start
- Mar 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in rheumatoid arthritis (RA), sponsored by Reade Rheumatology Research Institute. Started Mar 2020; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04222920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222920.